Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts.
Lymphopenia enhances the effectiveness of adoptive immunotherapy by facilitating expansion of transferred T cells but also limits the T-cell repertoire available to mediate immune responses and, in humans, is associated with chronic immune dysfunction. Previous studies concluded that lymphopenia augments adoptive immunotherapy by diminishing Tregs and increasing homeostatic cytokines. We sought to determine whether targeted therapies that replicate the physiology of lymphopenia in lymphoreplete hosts could provide a similarly supportive milieu. Pmel-1 T cells were transferred to B16-bearing lymphopenic versus lymphoreplete mice receiving alphaCD25 and/or recombinant human interleukin-7. Although CD25-based Treg depletion was inefficient because of peripheral expansion of CD4+CD25-FOXP3+ cells, outcomes were better in alphaCD25-treated lymphoreplete hosts than in lymphopenic hosts, and adoptive immunotherapy was most effective in lymphoreplete hosts receiving alphaCD25 plus recombinant human interleukin-7. Lymphopenic hosts supported increased proliferation of adoptively transferred antigen-specific T cells, but cells transferred to lymphoreplete recipients receiving targeted therapies showed superior function. Further, determinant spreading was substantial in lymphoreplete hosts but absent in lymphopenic hosts. These results demonstrate that targeted therapies delivered to mimic the "physiology of lymphopenia" enhance the efficacy of adoptive immunotherapy in lymphoreplete hosts and provide a potentially superior alternative to the induction of lymphopenia.
Cui
Yongzhi
Y
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Zhang
Hua
H
Meadors
Joanna
J
Poon
Rita
R
Guimond
Martin
M
Mackall
Crystal L
CL
D019264:Adoptive Transfer; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D015851:Interleukin-7 / Q000276:immunology / Q000494:pharmacology; D008231:Lymphopenia / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D051379:Mice; D018345:Mice, Knockout; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000637:transplantation*
C508605:IL7 protein, human; C508018:Il2ra protein, mouse; D053645:Interleukin-2 Receptor alpha Subunit; D015851:Interleukin-7
J Immunol. 1996 Jun 15;156(12):4609-16
8648103
Blood. 2001 Mar 15;97(6):1525-33
11238086
Blood. 1997 Nov 1;90(9):3789-98
9345067
Arch Intern Med. 1994 Jul 25;154(14):1561-73
7913314
Nat Immunol. 2009 Feb;10(2):149-57
19136960
Nat Rev Immunol. 2006 Aug;6(8):595-601
16868550
J Immunother. 2006 May-Jun;29(3):313-9
16699374
Blood. 2001 May 15;97(10):2983-90
11342421
J Clin Invest. 2007 May;117(5):1204-12
17476350
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19414-9
19033460
J Exp Med. 2003 Aug 18;198(4):569-80
12925674
J Immunol. 2007 Oct 1;179(7):4919-28
17878392
Semin Immunol. 2007 Oct;19(5):318-30
18023361
Semin Immunol. 2005 Jun;17(3):231-7
15826828
Immunol Res. 2008;42(1-3):182-96
18949448
Arthritis Rheum. 2008 Feb;58(2):370-5
18240243
Nature. 2006 Feb 9;439(7077):682-7
16382236
J Exp Med. 2005 Oct 3;202(7):907-12
16203864
Science. 2002 Oct 25;298(5594):850-4
12242449
J Clin Oncol. 2005 Apr 1;23(10):2346-57
15800326
Microbes Infect. 2002 Apr;4(5):531-7
11959508
Immunol Rev. 2008 Apr;222:5-8
18363991
Nat Rev Immunol. 2002 Feb;2(2):85-95
11910899
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16004-9
15505208
Cancer Res. 2002 Dec 15;62(24):7328-34
12499276
Am J Hematol. 1997 Feb;54(2):131-8
9034287
J Exp Med. 2008 Jul 7;205(7):1701-14
18573906
Nat Med. 2008 Nov;14(11):1264-70
18978797
J Transl Med. 2008 Mar 11;6:12
18334033
Immunol Today. 1997 May;18(5):245-51
9153957
Trends Immunol. 2005 Feb;26(2):111-7
15668127
J Immunol Methods. 2008 Apr 20;333(1-2):167-79
18295790
Nat Rev Cancer. 2008 Apr;8(4):299-308
18354418
J Autoimmun. 2000 Jun;14(4):275-7
10882052
J Immunother. 2008 Feb-Mar;31(2):189-98
18481388
N Engl J Med. 1995 Jan 19;332(3):143-9
7800006
J Clin Invest. 2007 Aug;117(8):2197-204
17657310
Immunity. 1999 Aug;11(2):173-81
10485652
Immunity. 1999 Aug;11(2):183-90
10485653
J Clin Invest. 2008 Jan;118(1):294-305
18060041
Immunol Rev. 1986 Jun;91:159-94
3525393
J Exp Med. 2002 Jun 17;195(12):1515-22
12070279
Immunol Rev. 2006 Aug;212:149-62
16903912
J Immunother. 2004 Sep-Oct;27(5):329-38
15314541
J Clin Invest. 2005 Apr;115(4):930-9
15776111
J Exp Med. 1998 Jul 20;188(2):277-86
9670040
J Immunol. 2005 Jun 1;174(11):6571-6
15905493
J Clin Oncol. 2008 Nov 10;26(32):5233-9
18809613
Clin Immunol. 2006 Aug;120(2):121-8
16766227
N Engl J Med. 2008 Jun 19;358(25):2698-703
18565862